Patients living with type 1 diabetes (PwT1D) still have trouble controlling their blood sugar, even with the latest treatments. PwT1D may have slow stomach emptying influencing blood glucose level. Treating this is an important goal. A recent study found that 30% of PwT1D had a slower gastric emptying rate, even though they had no other complications and were not experiencing any digestive issues. Slowing of gastric emptying is linked to gastric hypoglycaemia, which is a life-threatening condition that can affect quality of life, and to higher blood sugar level after eating. This can last throughout the night. Prokinetic treatments for the stomach are good for diabetic patients with slow digestion. These treatments help with stomach pain and, to a lesser extent, with hypoglycemia. However, there is no data on the benefits of such treatments in patients with no digestive symptoms, on glycaemic control as defined by continuous glucose monitoring data. In fact, this may be more relevant than HbA1c in patients with alternating hypo- and/or hyperglycaemia.
The investigator thinks that a prokinetic agent like domperidone could improve glycaemic control in PwT1D with slow gastric emptying and glycaemic imbalance.
This study tests how domperidone affects blood sugar levels in PwT1D. Patients will be administrated domperidone or a placebo for 28 days. The investigator will see how long T1D patients spend within their blood sugar target range over 14 days using a continuous glucose monitor.

Start Date01 Mar 2026

Sponsor / Collaborator-

CTR20252234

/ CompletedNot Applicable

多潘立酮片在中国健康受试者中的随机、开放、单次给药、两周期、双交叉空腹及随机、开放、单次给药、四周期、完全重复交叉餐后生物等效性试验

[Translation] A randomized, open-label, single-dose, two-period, double-crossover fasting and a randomized, open-label, single-dose, four-period, completely repeated crossover fed bioequivalence study of domperidone tablets in Chinese healthy subjects

主要研究目的：以白云山东泰商丘药业有限公司生产的多潘立酮片（规格：10 mg）为受试制剂，按生物等效性试验的有关规定，与西安杨森制药有限公司持证的多潘立酮片为参比制剂（商品名：吗丁啉®；规格 10 mg），对比在健康人体内的相对生物利用度，研究两制剂的人体生物等效性。次要研究目的：观察多潘立酮片受试制剂和参比制剂（吗丁啉®）在健康受试者中的安全性。

[Translation]

Main research purpose: Using domperidone tablets (specification: 10 mg) produced by Baiyunshan Dongtai Shangqiu Pharmaceutical Co., Ltd. as the test preparation, according to the relevant provisions of the bioequivalence test, and the domperidone tablets certified by Xi'an Janssen Pharmaceutical Co., Ltd. as the reference preparation (trade name: Motilium®; specification 10 mg), the relative bioavailability in healthy humans was compared to study the human bioequivalence of the two preparations. Secondary research purpose: Observe the safety of the test preparation of domperidone tablets and the reference preparation (Motilium®) in healthy subjects.

Start Date15 Jul 2025

Sponsor / Collaborator

Baiyun Mountain Dongtai Shangqiu Pharmaceutical Co. Ltd.

TCTR20250403003

/ RecruitingPhase 2/3IIT

Effectiveness of post-operative domperidone use for postoperative bowel ileus prevention after elective gynecologic laparotomy: a double-blinded randomized controlled trial

Start Date27 Mar 2025

Sponsor / Collaborator

Phramongkutklao Hospital

100 Clinical Results associated with Domperidone

100 Translational Medicine associated with Domperidone

100 Patents (Medical) associated with Domperidone

3,059

Literatures (Medical) associated with Domperidone

02 Feb 2026·Pakistan Journal of Pharmaceutical Sciences

AI-Driven ANN And RSM-CCD Integrated Optimization Of Cinnarizine-Domperidone Bilayer Tablet: In-Vitro Evaluation And In-Silico PBPK Modeling Using GastroPlus®

Article

Author: Jameel Khan, Sarah ; Siddique, Sidra ; Ahsan Ali, Syed ; Tasneem, Shumaila ; Ali, Aatka ; Iffat, Wajiha ; Naeem Muhammad, Iyad

Background: Response surface methodology coupled with the design of experiments identifies the optimal response surface function related to selected independent factors. Due to their rigid structures, they lack the learning capability from the developed response function. In contrast, a more advanced artificial intelligence-based tool, artificial neural network (ANN), offers an alternative to RSM-based regression methods. Objectives: This study was conducted to investigate the combined application of experimental design and a neural computing framework for modeling and optimization of a bilayer tablet with biphasic release of cinnarizine (CNZ) and domperidone (DOM), followed by in-silico physiologically-based pharmacokinetic (PBPK) modeling. Methods: The experimental data from the trial formulations supported by the central composite design (CCD) were trained using an artificial neural network. The predicted values of the input variables (HPMC K4M, sodium carbonate, croscarmellose and magnesium stearate) targeting the output responses (% drug release at 1h, 6h, 12h, and friability) were cross-validated using the numerical and graphical optimization technique of CCD. The in-silico PBPK modeling was used to measure relative bioavailability and simulate in-vivo plasma profiles under fasting state through GastroPlus® software. Results: The optimum quantities for developing a bilayer tablet —15% HMPC K4M, 3% sodium carbonate, 2% croscarmellose, and 1% magnesium stearate — were found to be very similar by both the CCD and ANN models, with desirability values close to 1. Moreover, ANOVA revealed no statistically significant difference between the optimized and predicted formulations. GastroPlus® assisted in the relative bioavailability evaluation of the optimized bilayer formulation, with an immediate-release domperidone and an extended-release cinnarizine layer, showing 89% and 81%, respectively. Conclusion: It is concluded that AI-powered modeling, especially the integration of ANN, accelerates innovation, leading to faster and smarter optimization of pharmaceutical formulations.

01 Feb 2026·JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY

Antiemetic Efficacy of Esculetin via Dopaminergic, Serotonergic, and Muscarinic Pathway Modulation: Insights From In Vivo and In Silico Studies

Article

Author: Oni, Israt Jahan ; Alfaifi, Mohammed ; Munni, Mst Muslima ; Hossen, Rakib ; Chowdhury, Raihan ; Islam, Muhammad Torequl ; Saha, Chinmoy Kumar ; Ajmee, Afiya ; Bithi, Sumaya Akter ; Mia, Emon ; Chakrabarty, Anike ; Al Hasan, Md. Sakib

ABSTRACT:

Esculetin (ELN), a naturally occurring coumarin derivative, possesses a range of pharmacological activities, yet its antiemetic potential remains underexplored. This study assessed the efficacy of ELN against copper sulfate pentahydrate (CuSO 4 .5H 2 O)‐induced emesis through a combined in vivo and in silico approach. In a validated chick emesis model, 3‐day‐old chicks were orally administered CuSO₄·5H 2 O (50 mg/kg) to induce vomiting. Standard antiemetic agents domperidone (DOM‐6 mg/kg), ondansetron (OND‐5 mg/kg), and hyoscine (HYO‐21 mg/kg) served as reference drugs. ELN was tested at doses of 5, 10, and 20 mg/kg, both as monotherapy and in combination with standard drugs, to evaluate dose−response relationships and potential drug−drug interactions. ELN‐20 demonstrated the most pronounced efficacy among the individual doses, producing the longest latency, surpassing the standard treatments OND, DOM, and HYO. Furthermore, the combination therapies ELN‐10 + DOM‐6 and ELN‐10 + HYS‐21 showed marked improvements, suggesting a synergistic interaction that enhances the overall therapeutic effect. Molecular docking studies were performed to investigate ELN's binding affinity (BA) with key emetogenic receptors, including dopaminergic (D 2 , D 3 ), serotonergic (5‐HT 3 ), and muscarinic (M 1 –M 5 ) subtypes. Docking results demonstrated supportive, moderate binding across dopaminergic (D 2, D 3 ), serotonergic (5‐HT 3 ), and muscarinic (M 1 –M 5 ) receptors, which, together with in vivo efficacy and synergistic effects with standard antiemetics, suggest a multi‐receptor involvement rather than definitive receptor blockade. Given its efficacy and multi‐target profile, ELN shows promise as a novel candidate for emesis management, warranting further preclinical and clinical investigations.

01 Dec 2025·SAGE Open Medical Case Reports

A rare case of antidepressant discontinuation syndrome triggered by domperidone: Clinical insights and literature review

Article

Author: Gajebasia, Niman ; Barkho, Ashour ; Elhusein, Bushra

Antidepressant discontinuation syndrome is commonly observed among patients who abruptly discontinue or reduce the dosage of an antidepressant that has been administered for at least 6 weeks. Common manifestations may include flu-like symptoms, insomnia, nausea, impaired balance, sensory disturbances, headache, irritability, anxiety, and hyperarousal. These symptoms are typically mild, persist for 1–2 weeks, and resolve upon resumption of the medication. The probability of developing this syndrome increases with the prescribed pharmacological agent’s prolonged treatment duration and shorter half-life. Before prescribing antidepressants, it is imperative to inform patients about the potential complications associated with the sudden discontinuation of the medication. Understanding this phenomenon can help prevent future incidents and reduce nonadherence risk. The majority of antidepressants possess the potential to induce antidepressant discontinuation syndrome. This case report presents a unique instance of discontinuation syndrome in a 50-year-old female patient with major depressive disorder who had been effectively managed on desvenlafaxine for several years. After initiating domperidone for chemotherapy-induced nausea, she experienced “brain zaps” and other symptoms consistent with antidepressant discontinuation syndrome. Upon cessation of domperidone, her symptoms rapidly resolved. This report examines potential interactions between domperidone and desvenlafaxine, emphasizing the necessity for clinicians to be cognizant of possible drug interactions that may precipitate discontinuation symptoms.

News (Medical) associated with Domperidone

29 Sep 2025

·www.drugs.com

Recommendations Issued for Diagnosing, Managing Gastroparesis

MONDAY, Sept. 29, 2025 -- In a clinical practice guideline issued by the American Gastroenterological Association and published in the October issue of Gastroenterology , conditional recommendations are presented for the diagnosis and management of gastroparesis . Kyle Staller, M.D., M.P.H., from Massachusetts General Hospital and Harvard Medical School in Boston, and colleagues assessed the evidence and developed recommendations for ensuring an accurate diagnosis and management of patients with idiopathic gastroparesis or gastroparesis related to diabetes. Twelve recommendations were agreed upon by the guideline panel. For individuals with suspected gastroparesis, a conditional recommendation was made against using two-hour gastric emptying testing and in favor of four-hour testing. Conditional recommendations were made for use of metoclopramide and erythromycin in patients with gastroparesis and against the use of domperidone, prucalopride, aprepitant, nortriptyline, buspirone, and cannabidiol as first-line therapies. In addition, routine use of gastric per-oral endoscopic pyloromyotomy or gastric electrical stimulation is not recommended for patients with gastroparesis; these treatments should be used for select patients with symptoms refractory to medical therapies. There were no recommendations made for use of surgical pyloromyotomy and surgical pyloroplasty. "These are not hard 'yes' or 'no' rules," Staller said in a statement. "If a treatment is 'suggested against,' it doesn't mean never, since it could still be right for some patients. The goal is for patients and providers to weigh benefits, risks, and personal goals." Abstract/Full Text

Biosimilar

24 Apr 2025

·pharma.economictimes.indiatimes.com

Drugs panel considering proposal to rein in sale of OTC medicines to prevent misuse

New Delhi: India's top advisory board on drugs is considering a plan to rein in the sale of commonly used over-the-counter (OTC) medications to prevent misuse and ensure patient safety, said people with knowledge of the matter. Under the proposal, only 27 drugs can be sold without a doctor's prescription, that too with curbs on dosage and amounts. On the list are antipyretics, painkillers, antacids, cough syrups, oral contraceptives, antiseptics, laxatives, nasal sprays, domperidone (anti-emetic), iron and folic acid tablets, besides SOS medication. Several drugs that are currently being dispensed without the need for a prescription have been excluded, as the sub-committee is of the view that these should only be sold on doctor's approval. The Drugs Technical Advisory Board is expected to meet this week to decide on the recommendation. The Central Drugs Standard Control Organisation, the country's regulatory authority, last year formed an eight-member sub-committee to draw up a framework for OTC drugs. It was asked to create a mechanism for determining which medications would qualify as OTC drugs, incorporating suggestions from clinicians. Dr Anupam Prakash, the OTC sub-committee chairman, confirmed that the report had been submitted. "The aim was to increase the accessibility of commonly used medicines and at the same time ensure safety of the patient," he said. "All SOS medicines have been included on the list. We have dropped many medicines which are available at pharmacists and should only be dispensed with prescriptions," said Prakash. For those on the OTC list, the sub-committee has recommended "smaller" pack sizes appropriate for the duration of the treatment to promote safe use, especially for medications with the potential risk of misuse or overdosing. "One of the recommendations is that the pack size of the drug should not exceed the maximum dose recommended for five days. The pack size (2-3-5) has been recommended, depending on the toxicity of the drug," said one of the persons cited. In other words, the shortlisted drugs can be sold over the counter without the prescription of a registered medical practitioner only if the maximum duration of treatment or use does not exceed five days. The term 'over the counter' is not defined in India's Drugs and Cosmetics Act, 1945, unlike in the US, the UK and elsewhere, which have well-defined guidelines on drugs that can be sold without a prescription. By Teena Thacker ,

06 Nov 2024

·pharma.economictimes.indiatimes.com

Paracetamol to PAN-D: CDSCO finds over 50 sub-standard drugs. Check full list of medicines

New Delhi: The Central Drugs Standard Control Organisation ( CDSCO ) has identified over 50 drugs which have failed in the drug test. In its latest report, the controller said 50 drugs including Paracetamol are "not of standard quality" (NSQ). The report has also flagged calcium and vitamin D3 supplements, anti-diabetes pills, and high blood pressure medicines. Paracetamol tablets from Karnataka Antibiotics & Pharmaceuticals Ltd were specifically mentioned for quality concerns. The report listed a total of 48 drugs in the NSQ category, including a Gauze Roll Non Sterile Roller Bandage. NSQ alerts come from monthly random sampling conducted by state drug officers. Some of the medicines were produced by companies like Hetero Drugs, Alkem Laboratories, Hindustan Antibiotics Limited (HAL), Karnataka Antibiotics & Pharmaceuticals Ltd, Meg Lifesciences, and Pure & Cure Healthcare. Additionally, the CDSCO shared another list that features five more drugs that failed quality tests. The pharmaceutical companies denied responsibility for these drugs. They claim they are "spurious," and one response from a company stated, "The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug. The product is purported to be spurious; however, the same is subjected to outcome of investigation." CDSCO NSQ Test: Full list of drugs and their manufacturers Here is the list of drugs that failed the CDSCO test along with the manufacturers: Amoxicillin And Potassium Clavulanate Tablets IP (Clavam 625) - M/s. Alkem Health Science Amoxicillin & Potassium Clavulanate Tablets (Mexclav 625) - M/s. Meg Lifesciences Calcium And Vitamin D3 Tablets IP (Shelcal 500) - M/s. Pure & Cure Healthcare Pvt. Ltd. Metformin Hydrochloride Sustained-release Tablets IP (Glycimet-SR-500) - M/s. Scott-Edil Pharmacia Ltd. Vitamin B Complex with Vitamin C Softgels - M/s. Asoj Soft Caps Pvt. Ltd. Rifmin 550 (Rifaximin Tablets 550 mg) - M/s. Legen Healthcare Pantoprazole Gastro-Resistant and Domperidone Prolonged-Release Capsules IP (Pan - D) - M/s. Alkem Health Science Paracetamol Tablets IP 500 mg - M/s. Karnataka Antibiotics and Pharmaceuticals Ltd. Montair LC Kid (Montelukast Sodium & Levocetirizine Hydrochloride Dispersible Tablets) - M/s. Pure & Cure Healthcare Pvt. Ltd. Compound Sodium Lactate Injection IP (Ringer Lactate Solution for Injection) (RL 500 ml) - M/s. Vision Parenteral Pvt. Ltd. Fexofenadine Hydrochloride Tablets IP 120 mg - M/s. Maxtar Bio-Genics Laxnorm Solution (Lactulose Solution USP) - M/s. Athens Life Sciences Heparin Sodium Injection 5000 Units (Hostranil Injection) - M/s. Health Biotech Ltd. Buflam Forte Suspension (Ibuprofen & Paracetamol Oral Suspension) - M/s. Ornate Pharma Pvt. Ltd. Cepodem XP 50 Dry Suspension (Cefpodoxime Proxetil and Potassium Clavulanate Oral Suspension) - M/s. Hetero Labs Limited Nimesulide, Paracetamol and Chlorzoxazone Tablets (NICIP MR) - M/s. HSN International Rolled Gauze (Non-Sterilized) - M/s. Blazon India Ciprofloxacin Tablets IP 500 mg (Ocif-500) - M/s. Ornate Labs Pvt. Ltd. Nimesulide, Phenylephrine Hydrochloride & Levocetirizine Dihydrochloride Tablets (Nunim-Cold) - M/s. Unispeed Pharmaceuticals Pvt. Ltd. Adrenaline Injection IP Sterile 1 ml - M/s. Alves Healthcare Pvt. Ltd. Compound Sodium Lactate Injection IP (Ringer Lactate Solution for Injection) RL 500ml - M/s. Vision Parentral Pvt. Ltd. Vingel XL Pro Gel (Diclofenac Diethylamine, Linseed Oil, Methyl Salicylate, and Menthol Gel) - M/s. Universal Twin Labs Atropine Sulphate Injection IP 2 ml - M/s. Nandani Medical Laboratories Pvt. Ltd. Cefoperazone & Sulbactam For Injection (Todaycef 1.5 G) - M/s. Daxin Pharmaceuticals Pvt. Ltd. Heparin Sodium Injection IP 25000 IU / 5ml - M/s. Scott-Edil Pharmacia Ltd. Cefepime & Tazobactam for Injection (Crupime - TZ Kid Injection) - M/s. Cosmas Research Lab. Ltd. Atropine Sulphate Injection IP (Atropine Sulphate) - M/s. Priya Pharmaceuticals Salbutamol, Bromhexine HCI, Guaifenesin and Menthol Syrup (Acozil Expectorant) - M/s. Antila Lifesciences Pvt. Ltd. Diclofenac Sodium IP - M/s. Sara Exports Ltd. Escitalopram and Clonazepam Tablets IP (Klozaps-ES Tablets) - M/s. Digital Vision Phenytoin Sodium Injection USP - M/s. Health Biotech Ltd. Paracetamol, Phenylephrine Hydrochloride and Cetirizine Hydrochloride Suspension (Cethel Cold DS Suspension) - M/s. Win Cure Pharma Calcium 500 mg with Vitamin D3 250 IU Tablets IP - M/s. Life Max Cancer Laboratories Amoxycillin and Potassium Clavulanate Tablets IP 625 mg (Renamega- CV 625) - M/s. Malik Lifesciences Pvt. Ltd. Olmesartan Medoxomil Tablets IP 40 mg - M/s. Life Max Cancer Laboratories INFUSION SET-NV - M/s. Medivision Healthcare Telmisartan Tablets IP 40 mg - M/s. Life Max Cancer Laboratories Alprazolam Tablets IP 0.25 mg (Erazol-0.25 Tablets) - M/s. Elikem Pharmaceuticals Pvt. Ltd. Glimepiride Tablets IP (2 mg) - M/s. Mascot Health Series Pvt. Ltd. Calcium and Vitamin D3 Tablets IP - M/s. Unicure India Ltd. Metronidazole Tablets IP 400mg - M/s. Hindustan Antibiotics Ltd. Paziva -40 - M/s. Gnosis Pharmaceuticals Pvt. Ltd. Pantomed -40 - Digital Vision 176 Cefixime Oral Suspension IP (Dry Syrup) - Nestor Pharmaceuticals Ltd. Moxymed CV - Alexa Pharmaceuticals Frusemide Injection IP 20 mg - Nestor Pharmaceuticals Ltd. Kudajarishtam - Bala Herbals Tab Nodosis - Steadfast Medishield Pvt. Ltd. Haridrakhanda - Bhaskara Vilasam Vaidyasala Pantoprazole Inj. BP 40 mg - Kerala Medical Services Corporation Ltd. Yogaraja Guggulu - Bhaskara Vilasam Vaidyasala PANCEF-OF - Aglomed Ltd.

Drug Approval

100 Deals associated with Domperidone

External Link

KEGG	Wiki	ATC	Drug Bank
D01745	Domperidone	A03FA03	DB01184

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Gastrointestinal Diseases	Japan	Kyowa Hakko Kirin Pharma, Inc.	01 Sep 1982
Nausea	Japan	Kyowa Hakko Kirin Pharma, Inc.	01 Sep 1982
Vomiting	Japan	Kyowa Hakko Kirin Pharma, Inc.	01 Sep 1982
Chronic gastritis	Japan	Kyowa Kirin Co., Ltd.	15 Jun 1982
Diarrhea, Infantile	Japan	Kyowa Kirin Co., Ltd.	15 Jun 1982
Gastroptosis	Japan	Kyowa Kirin Co., Ltd.	15 Jun 1982
Heartburn	Japan	Kyowa Kirin Co., Ltd.	15 Jun 1982
Nausea and vomiting	Japan	Kyowa Kirin Co., Ltd.	15 Jun 1982
Postgastrectomy Syndromes	Japan	Kyowa Kirin Co., Ltd.	15 Jun 1982
Respiratory Tract Infections	Japan	Kyowa Kirin Co., Ltd.	15 Jun 1982

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastroenteritis	Phase 3	Austria	Janssen-Cilag International NV	07 Dec 2015
Gastroenteritis	Phase 3	Belgium	Janssen-Cilag International NV	07 Dec 2015
Gastroenteritis	Phase 3	Russia	Janssen-Cilag International NV	07 Dec 2015
Gastroenteritis	Phase 3	South Africa	Janssen-Cilag International NV	07 Dec 2015
Gastroenteritis	Phase 3	Spain	Janssen-Cilag International NV	07 Dec 2015
Gastroenteritis	Phase 3	United Kingdom	Janssen-Cilag International NV	07 Dec 2015
Norovirus Infections	Phase 3	Austria	Janssen-Cilag International NV	07 Dec 2015
Norovirus Infections	Phase 3	Belgium	Janssen-Cilag International NV	07 Dec 2015
Norovirus Infections	Phase 3	Russia	Janssen-Cilag International NV	07 Dec 2015
Norovirus Infections	Phase 3	South Africa	Janssen-Cilag International NV	07 Dec 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04208698 (CTgov)	Phase 2	Diabetic Gastroparesis	2	CIN-102 Dose 1 (CIN-102 Tablets Dose 1)	hhwridwhci(gxxstekmwa) = dhpvfgkmty mboqxkkujn (kfdnjjbefz, gubyflqmva - ojtrhypbav) View more	-	10 Aug 2021
NCT04208698 (CTgov)	Phase 2	Diabetic Gastroparesis	2	Placebo for CIN-102 (Placebo for CIN-102 Dose 1)	hhwridwhci(gxxstekmwa) = clniadjuzb mboqxkkujn (kfdnjjbefz, jssvobyzpf - rbdvooyumn) View more	-	10 Aug 2021
NCT04024865 (Pubmed \| CMAJ Open)	Not Applicable	-	184,929	Domperidone	hjhpuyjzgo(dpvarvzbtw) = frdywwoayd eleivnkuxg (tahusweyio )	-	01 Apr 2021
NCT03662113 (Pubmed \| Transl Pediatr)	Not Applicable	-	200	Domperidone	gtlzqeuvng(tqmegjezru) = aoklnqqxvx elztoqlays (yeptupdwsl, 44.8 - 117.5) View more	Negative	01 Feb 2021
NCT03662113 (Pubmed \| Transl Pediatr)	Not Applicable	-	200	domperidone (Control)	gtlzqeuvng(tqmegjezru) = mqjlfgjayr elztoqlays (yeptupdwsl, 42.0 - 128.0) View more	Negative	01 Feb 2021
NCT02308137 (not available, ACTRIMS2020)	Phase 2	Multiple Sclerosis, Secondary Progressive prolactin levels	110	Domperidone 10mg	kmtvzvkdgj(mdqquqxfsd) = crtfjkgjvf odmzgqnvse (gpucetwrtg )	Negative	11 May 2020
NCT02493049 (ECTRIMS2018)	Phase 2	Multiple Sclerosis, Relapsing-Remitting Add-on	15	Domperidone	ektvjsrdag(audzruuksx) = hkapjyxmbd lifrpacyxw (vblwkrsiga, 5.2)	-	09 Oct 2018
NCT00760461 (CTgov)	Phase 2	Gastroparesis	44	Domperidone	uzupzoicec(meskybaksy) = tqtohhpnon uyggwsqhua (fulxoastqq, hfypjjdqzb - yavnctznhd) View more	-	18 Aug 2017
NCT01878526 (GERD-SSc, CTgov)	Phase 3	Scleroderma, Systemic \| Gastroesophageal Reflux	80	placebo (for domperidone)+Alginic acid (Omeprazole Plus Alginic Acid and Placebo of Domperidone)	tvlskkgfch(jhtskffdxg) = euqbuccauu hkvlgkcbok (xtuptayilz, 13.1) View more	-	27 Mar 2017
NCT01878526 (GERD-SSc, CTgov)	Phase 3	Scleroderma, Systemic \| Gastroesophageal Reflux	80	placebo (of alginic acid)+Domperidone (Omeprazole Plus Domperidone and Placebo of Alginic Acid)	tvlskkgfch(jhtskffdxg) = vxpavrinwo hkvlgkcbok (xtuptayilz, 13.9) View more	-	27 Mar 2017
NCT01878526 (Pubmed \| Rheumatology (Oxford))	Phase 3	Scleroderma, Systemic \| Gastroesophageal Reflux Add-on	80	Domperidone plus algycon placebo	sxkbnwihzt(vieejcwvai) = ehcjkvfxob txvfgbftil (trcnzhkrdw )	-	01 Feb 2017
NCT01878526 (Pubmed \| Rheumatology (Oxford))	Phase 3	Scleroderma, Systemic \| Gastroesophageal Reflux Add-on	80	Algycon plus domperidone placebo	sxkbnwihzt(vieejcwvai) = mqemmozmyq txvfgbftil (trcnzhkrdw )	-	01 Feb 2017
NCT01711918 (CTgov)	Not Applicable	Nausea \| Gastroparesis \| Vomiting	9	Domperidone	ywfjgvwxbt = ylitzgntgu asptbushft (qdsgmhilrx, ppnnuwenvu - sjaqrpakgn) View more	-	19 Dec 2016
NCT00552422 (CTgov)	Not Applicable	Gastroparesis \| Gastroesophageal Reflux	6	domperidone	bentnrelhf = jnijyoxofn cbimaquuve (kpqnznjzpj, zujakaxbpy - yjnxihohct)	-	10 Jul 2015

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Domperidone

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation